-+ 0.00%
-+ 0.00%
-+ 0.00%

Shenzhen GTJA co-leads Changyu Pharma’s CNY 250 million Series D financing round

PUBT·07/28/2026 07:48:41
Listen to the news
Shenzhen GTJA co-leads Changyu Pharma’s CNY 250 million Series D financing round
  • Shenzhen GTJA Investment Group co-led Changyu Pharma’s D round, raising CNY 250 million via the GTJA Nanning Fuyi fund.
  • Changyu Pharma is a Shanghai-based biotech developing non-opioid pain and neurology drugs to reduce or replace opioid use.
  • Proceeds earmarked for a U.S. Phase III acute-pain trial of lead candidate XG005, with additional funding for pipeline development and global rollout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen GTJA Investment Group Co Ltd published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.